



HOKKAIDO UNIVERSITY

Title	Effects of valproic acid on syncytialization in human placental trophoblast cell lines
Author(s)	Nanami, Ohyama; Ayako, Furugen; Riko, Sawada et al.
Citation	Toxicology and Applied Pharmacology, 474, 116611 https://doi.org/10.1016/j.taap.2023.116611
Issue Date	2023-09-01
Doc URL	https://hdl.handle.net/2115/93037
Rights	© 2023. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
Rights(URL)	https://creativecommons.org/licenses/by-nc-nd/4.0/
Type	journal article
File Information	HUSCAP_F.pdf



1 **Effects of valproic acid on syncytialization in human placental trophoblast cell lines.**

2
3 Nanami Ohyama^a, Ayako Furugen^{a*}, Riko Sawada^a, Ryoichi Aoyagi^a, Ayako Nishimura^b, Takeshi
4 Umazume^c, Katsuya Narumi^a, Masaki Kobayashi^{a*}

5
6 ^aLaboratory of Clinical Pharmaceutics & Therapeutics, Division of Pharmasciences, Faculty of
7 Pharmaceutical Sciences, Hokkaido University

8 ^bDepartment of Pharmacy, Hokkaido University Hospital

9 ^cDepartment of Obstetrics, Hokkaido University Hospital

10
11 *To whom correspondence should be addressed:

12 Masaki Kobayashi, Ph.D. Phone/Fax: +81-11-706-3772/3770; E-mail: masaki@pharm.hokudai.ac.jp.

13 Ayako Furugen, Ph.D. Phone/Fax: +81-11-706-3235/3235; E-mail: afurugen@pharm.hokudai.ac.jp.

14 Laboratory of Clinical Pharmaceutics & Therapeutics, Division of Pharmasciences, Faculty of
15 Pharmaceutical Sciences, Hokkaido University, Kita-12-jo, Nishi-6-chome, Kita-ku, Sapporo 060-
16 0812, Japan

17
Abbreviations: ASCT2, alanine serine cysteine transporter 2; CBZ, carbamazepine; CLB, clobazam;
Col, collagen; CT, cytotrophoblast; ELISA, enzyme-linked immunosorbent assay; FK, forskolin,
GBP, gabapentin; GCM1, glial cells missing transcription factor 1; HDAC, histone deacetylase; hCG,
human chorionic gonadotropin; hPL, human placental lactogen; LCM, lacosamide; LEV,
levetiracetam; LTG, lamotrigine; MFSD2, major facilitator superfamily domain-containing protein 2;
MRP4, multidrug resistance protein 4; ST, syncytiotrophoblast; TPM, topiramate; TS, trophoblast
stem; VPA, valproic acid; YWHAZ, tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein zeta

18 **Abstract**

19 The placenta is a critical organ for fetal development and a healthy pregnancy, and has
20 multifaceted functions (e.g., substance exchange and hormone secretion). Syncytialization of
21 trophoblasts is important for maintaining placental functions. Epilepsy is one of the most common
22 neurological conditions worldwide. Therefore, this study aimed to reveal the influence of antiepileptic
23 drugs, including valproic acid (VPA), carbamazepine, lamotrigine, gabapentin, levetiracetam,
24 topiramate, lacosamide, and clobazam, at clinically relevant concentrations on syncytialization using
25 *in vitro* models of trophoblasts. To induce differentiation into syncytiotrophoblast-like cells, BeWo
26 cells were treated with forskolin. Exposure to VPA was found to dose-dependently influence
27 syncytialization-associated genes (*ERVW-1*, *ERVFRD-1*, *GJA1*, *CGB*, *CSH*, *SLC1A5*, and *ABCC4*) in
28 differentiated BeWo cells. Herein, the biomarkers between differentiated BeWo cells and the human
29 trophoblast stem model (TS^{CT}) were compared. In particular, *MFSD2A* levels were low in BeWo cells
30 but abundant in TS^{CT} cells. VPA exposure affected the expression of *ERVW-1*, *ERVFRD-1*, *GJA1*, *CSH*,
31 *MFSD2A*, and *ABCC4* in differentiated cells (ST-TS^{CT}). Furthermore, VPA exposure attenuated BeWo
32 and TS^{CT} cell fusion. Finally, the relationships between neonatal/placental parameters and the
33 expression of syncytialization markers in human term placentas were analyzed. *MFSD2A* expression
34 was positively correlated with neonatal body weight, head circumference, chest circumference, and
35 placental weight. Our findings have important implications for better understanding the mechanisms
36 of toxicity of antiepileptic drugs and predicting the risks to placental and fetal development.

37

38 **Key words:** antiepileptic drug, differentiation, placenta, syncytialization, trophoblast, valproic acid

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56 1. Introduction

57 The placenta is a temporal and essential organ for a healthy pregnancy and proper fetal
58 development. In particular, the placenta has multifaceted functions, such as nutrient transport to the
59 fetus, metabolism and elimination of products, gas exchange, and hormone secretion. Placental
60 trophoblasts play an important role in these functions. Human cytotrophoblast progenitor cells
61 differentiate via two pathways: villous trophoblasts and extravillous trophoblasts (Ji et al., 2013). In
62 the villous pathway, mononucleated cytotrophoblasts (CTs) fuse to form multinucleated
63 syncytiotrophoblasts (ST), resulting in a syncytial layer that covers the placental villi. The
64 syncytialization of trophoblast cells, including differentiation and fusion, is important for adequate
65 placental development and pregnancy (Gupta et al., 2016). Both biochemical and morphological
66 alterations occur during the differentiation of CT cells into ST cells (Handwerger, 2010). The human
67 endogenous retrovirus envelope proteins, syncytin-1 (*ERVW-1*) and syncytin-2 (*ERVFRD-1*), are
68 involved in the fusion of trophoblast cells (Ji et al., 2013). Syncytin-1 exists in ST cells, and its
69 expression is maintained throughout gestation. In contrast, the expression of syncytin-2 slowly
70 decreases throughout gestation (Okahara al., 2004). Human chorionic gonadotropin (hCG/*CGB*) and
71 human placental lactogens (hPL/*CSH*) are hormones produced during pregnancy. hCG increases
72 progesterone production and contributes to syncytialization (Ji et al., 2013). hPL is a polypeptide
73 hormone synthesized by trophoblasts and secreted into maternal blood. hPL is associated with the
74 regulation of lipid and carbohydrate metabolism in the mother and is essential for energy homeostasis
75 (Costa, 2016). These proteins have been employed as syncytialization markers. The alanine serine

76 cysteine transporter 2 (*ASCT2/SLC1A5*) acts as a receptor of syncytin-1 for cell fusion (Lavillette et
77 al., 2002), and the major facilitator superfamily domain-containing protein 2 (*MFSD2/MFSD2A*), is a
78 receptor for syncytin-2 (Esnault et al., 2008). Glial cells lacking transcription factor 1 (*GCM1/GCM1*)
79 is a transcription factor that regulate syncytin-1 expression (Huang et al., 2014). Multidrug resistance
80 protein 4 (*MRP4/ABCC4*) is a transporter involved in cAMP efflux (Copsel et al., 2011). As cAMP is
81 a key regulator of trophoblast differentiation (Handwerger, 2010), we monitored the expression of
82 *MRP4* as a potential marker in this study. The gap junction protein, Connexin-43 (*GJA1*), is involved
83 in the fusion of trophoblasts (Frendo et al., 2003).

84 Anomalies in the expression of hormones and syncytialization-associated genes have been
85 associated with obstetric complications. Studies have reported the downregulation of syncytin-1 in
86 placentas with fetal growth restriction and preeclampsia (Lee et al., 2001; Knerr et al., 2002; Chen et
87 al., 2006; Langbein et al., 2008; Ruebner et al., 2010). Furthermore, alterations in syncytin-2, *MFSD2*,
88 hCG, and connexin-43 in the placenta are associated with these complications (Langbein et al., 2008;
89 Ruebner et al., 2010; Otto et al., 2015). The levels of syncytin-2 and *MFSD2* have been reported to
90 decrease in gestational diabetic placentas (Soygur et al., 2016). An evaluation of alterations in these
91 placental markers is thus important for predicting fetal and maternal health.

92 The expression of syncytialization-associated proteins and hormones can be altered by
93 maternal conditions, such as exposure to substances. In fact, environmental contaminants have been
94 reported to disrupt hormone secretion (Le et al., 2014; Drwal et al., 2020). Exposure to benzo(a)pyrene

95 induced the differentiation and production of hCG in human choriocarcinoma BeWo cells (Le et al.,
96 2014). Further, polycyclic aromatic hydrocarbons were found to modulate hCG, hPL, and placental
97 growth factor levels in the human choriocarcinoma cell lines, BeWo and JEG-3 (Drwal et al., 2020).
98 High concentrations of high-density lipoprotein cholesterol (HDL) and oxidized HDL reduce hCG
99 secretion, GCM1 expression, and cell fusion in BeWo cells (Wang et al., 2021). Delta-9-
100 tetrahydrocannabinol attenuates syncytialization in BeWo cells (Walker et al., 2020). Selective
101 serotonin reuptake inhibitors have been reported to affect the fusion of primary villous trophoblasts
102 and modify hCG secretion from BeWo cells (Clabault et al., 2018).

103 Pharmacotherapy during pregnancy requires consideration of the benefits to the mother and
104 risks to the fetus. Epilepsy is one of the most common neurological conditions (Avachat et al., 2018).
105 Recently, a variety of antiepileptic drugs have been approved and have contributed to the treatment of
106 seizures in epileptic patients (Avachat et al., 2018). Most pregnant women with epilepsy require
107 continued antiepileptic drugs as uncontrolled seizures may have adverse effects on the mother and
108 fetus (Tomson et al., 2011). Furthermore, unintended pregnancy commonly occurs in women with
109 epilepsy (Herzog et al., 2017). Therefore, a toxicological assessment of antiepileptic drugs for
110 placental function could provide meaningful information for estimating risks to the fetus.

111 Exposure to certain antiepileptic drugs increases the risks to the fetus. Especially, the use of
112 valproic acid (VPA) during the periconceptional period dose-dependently increased the risk of fetal
113 malformations (Tomson et al., 2011). Besides, exposure to high-dose VPA during pregnancy increases

114 the risk of impaired cognitive function, compared with that associated with the exposure to other
115 commonly used antiepileptic drugs (Meador et al., 2013). *In utero* exposure of VPA was reported to
116 be associated with an increased risk of autism spectrum disorders in the offspring (Christensen et al.,
117 2013). Therefore, VPA should be avoided in pregnant women with epilepsy, except in cases where
118 other medications are ineffective or not tolerated (Kim et al., 2019). Furthermore, the use of
119 carbamazepine (CBZ) at a high dose, phenobarbital, and phenytoin increased the risk of teratogenicity
120 (Meador and Loring, 2016; Tomson et al., 2018). Newer antiepileptic drugs are more commonly used
121 during pregnancy (Vajda et al., 2014). Among these, the use of topiramate (TPM) in early pregnancy
122 increased the risk of teratogenicity (Hernandez-Diaz et al., 2018). Clobazam (CLB) has been reported
123 to have a higher risk profile (Thomas et al., 2017). Risk of major malformations associated with
124 lamotrigine (LTG) and LEV have been reported to be within the range of risk in individuals who are
125 unexposed to antiepileptic drugs (Tomson et al., 2018). LTG and LEV are recommended for women
126 of reproductive age with epilepsy. Based on these observations, consideration should be given to the
127 type and dose of antiepileptic drugs when used for women of reproductive age (Pennell, 2018).
128 However, in a population-based longitudinal cohort study, a noticeable proportion of women were
129 treated with VPA and TPM despite known teratogenicity risks (Kim et al., 2019). Increases in the
130 prescription of gabapentin (GBP) and pregabalin were observed in the U.K. after 2012, although data
131 on GBP use during pregnancy are insufficient to make a conclusion about its potential risk to the fetus
132 (Hurault-Delarue et al., 2019). Lacosamide (LCM) is a third-generation antiepileptic drug. Although

133 data on the use of LCM during pregnancy is limited, in a recent study, increased occurrences of
134 pregnancies in women administered newer antiepileptic drugs, including LCM, were reported
135 (Hoeltzenbein et al., 2023). To date, valproic acid VPA and LEV have been reported to reduce the
136 secretion of hormones, such as hCG, progesterone, and 17 β -estradiol, from BeWo cells (Kwiecińska
137 et al., 2011). However, the assay was conducted under undifferentiated conditions and the detailed
138 effects of antiepileptic drugs on trophoblast differentiation remain unclear.

139 Histone deacetylases (HDACs) play critical roles in trophoblast syncytialization (Maltepe et
140 al., 2005; Pan et al., 2008; Jaju Bhattad et al., 2020). The mammalian HDAC isoforms are classified
141 into four classes: class I (HDAC1–HDAC3 and HDAC8), class II (class IIa: HDAC4, HDAC5,
142 HDAC7, and HDAC9; class IIb: HDAC6 and HDAC10); class III (SIRT1–SIRT7); and class IV
143 (HDAC11) (Milazzo et al., 2020). HDACs are important for differentiation of trophoblasts and
144 trophoblast stem cells in mouse (Maltepe et al., 2005; Pan et al., 2008). Recently, HDAC inhibitors,
145 such as trichostatin A (a pan-HDAC inhibitor) and FK228 (an HDAC1/2 inhibitor) were reported to
146 inhibit human trophoblast fusion and the activity of HDAC1 and HDAC2 was shown to be important
147 for differentiation (Jaju Bhattad et al., 2020). VPA is widely known to exhibit inhibitory effects on
148 HDACs (Gurvich et al., 2004). In fact, as an HDAC inhibitor, VPA, in addition to the activators of
149 Wingless/Integrated (Wnt) and EGF and inhibitors of TGF- β and Rho-associated protein kinase
150 (ROCK), is used to maintain the stem cell-state of human trophoblast stem cells (Okae et al., 2018).
151 However, there are various isoforms of HDACs and the affinity of HDAC inhibitors for each isoform

152 is different (Milazzo et al., 2020). The pharmacological effects of VPA on syncytialization have not
153 been fully elucidated. Furthermore, TPM and major metabolite of LEV can inhibit HDACs, although
154 with lower potencies than VPA (Eyal et al., 2004). CBZ induced acetylation of histone H4 in HepG2
155 cells and inhibited HDAC3 and HDAC7 (Beutler et al., 2005). LCM reduced HDAC1 levels in the
156 cerebral cortex of rats (Bang et al., 2015). LCM was reported to enhance histone hyperacetylation in
157 BeWo cells (Granit et al., 2018). In this context, we focused on the effects of antiepileptic drugs,
158 especially VPA, on trophoblast syncytialization.

159 The current study aimed to reveal the effects of eight antiepileptic drugs, VPA, CBZ, LTG,
160 GBP, LEV, TPM, LCM, and CLB, at clinically relevant concentrations on trophoblast syncytialization.
161 These antiepileptic drugs are generally used for epilepsy, and are also prescribed for reproductive-aged
162 and pregnant women, as described above. We included various characteristic drugs considering clinical
163 situations known to be associated with risks to fetus (e.g., VPA, CBZ, and TPM), drugs that are
164 recommended for pregnant women (e.g., LTG and LEV), and drugs for which limited information on
165 usage among pregnant women is available (e.g., CLB, GBP, and LCM). Furthermore, we considered
166 the biochemical properties of antiepileptic drugs (e.g., VPA, CBZ, TPM, and LCM) that may affect
167 histone acetylation as selection criteria. BeWo cells were used as a trophoblast model to screen the
168 effects of these antiepileptic drugs. This cell line has the characteristics of human trophoblasts and has
169 been widely used to investigate syncytialization (Ji et al., 2013). BeWo cells can differentiate into ST-
170 like cells upon treatment with forskolin (FK), an adenylate cyclase activator (Handwerger, 2010).

171 Recently, Okae et al. established human trophoblast stem (TS) cells from CT cells isolated from first-
172 trimester placentas (Okae et al., 2018). This model is expected to be a useful tool for research on human
173 placental development and function. As an additional model, TS^{CT} cells were employed in this study.

174

175

176 **2. Materials and methods**

177 **2.1. Chemicals**

178 VPA and CLB were purchased from Sigma-Aldrich (St. Louis, MO, USA). LTG, GBP, LEV,
179 and TPM were purchased from Tokyo Chemical Industry (Tokyo, Japan). LCM was purchased from
180 Toronto Research Chemicals (North York, ON, Canada). CBZ and FK were purchased from Wako
181 Pure Chemical Industries (Osaka, Japan).

182

183 **2.2. Cell culture**

184 Human placental choriocarcinoma BeWo cells were cultured in Ham's F-12K (Kaighn's)
185 medium (Wako) supplemented with fetal bovine serum (15%) and penicillin-streptomycin (1%) at
186 37 °C with 5% CO₂, as described previously (Furugen et al., 2017). Human trophoblast stem (TS^{CT})
187 cells derived from human cytotrophoblasts (CT) were purchased from Riken Cell Bank (Saitama,
188 Japan) (CT29, RCB4937). TS^{CT} cells were cultured according to a previously reported protocol (Okae
189 et al., 2018). Briefly, TS^{CT} cells were seeded on collagen (Col IV)-coated dishes or plates, and cultured
190 in TS medium. The TS medium consisted of DMEM/F12 (Wako) supplemented with 0.1 mM 2-
191 mercaptoethanol (GIBCO), 0.2% FBS, 0.5% penicillin-streptomycin, 0.3% BSA (Wako), 1% ITS-X
192 supplement (Wako), 1.5 mg/ml L-ascorbic acid (Wako), 50 ng/mL EGF (Wako), 2 mM CHIR99021
193 (Wako), 0.5 mM A83-01 (Wako), 1 mM SB431542 (Wako), 0.8 mM VPA (Wako), and 5 mM Y27632
194 (Wako). Cells were cultured at 37 °C with 5% CO₂.

195

2.3. Differentiation of cells and exposure to antiepileptic drugs

To induce differentiation, BeWo cells were treated with medium containing 20 μ M FK or 0.1% dimethyl sulfoxide (DMSO) (as control) for 48 h. Antiepileptic drugs, including VPA, CBZ, LTG, GBP, LEV, TPM, LCM, and CLB, were dissolved as previously described (Kurosawa et al., 2018). Stock solutions of VPA, GBP, LEV, TPM, and LCM were dissolved in methanol. Stock solutions of CBZ, LTG, and CLB were dissolved in DMSO. They were further diluted with the cell culture medium (solvent final concentration $\leq 0.27\%$). After 2 days of culture, BeWo cells were exposed to antiepileptic drugs in the presence or absence of FK for 48 h. Equal volumes of the respective solvents were added to the cells to serve as a control. The concentrations of the antiepileptic drugs were 1 mM (VPA), 50 μ M (CBZ), 50 μ M (LTG), 100 μ M (GBP), 270 μ M (LEV), 50 μ M (TPM), 40 μ M (LCM), and 1 μ M (CLB). Antiepileptic drugs were exposed at high concentrations within the therapeutic range (Jacob and Nair, 2016). To assess the concentration dependence of the effects of VPA, we used clinically relevant range (250–1,000 μ M) of the drug. In plasma, the reference concentration range of VPA is between 50 and 100 μ g/mL (347–693 μ M) for epilepsy (Patsalos et al., 2018). The serum concentrations range from 50 μ g/mL to 100 or 150 μ g/mL (1040 μ M) (Sztajnkrzyca et al., 2002).

TS^{CT} cells (1.0×10^5 cells/well) were seeded on Col IV-coated 6-well plastic plates and cultured for three days in TS-medium. For induction of ST cells, the TS medium was changed to ST medium and the cells were cultured for 72 h. The ST-medium consisted of DMEM/F12 supplemented

215 with 0.1 mM 2-mercaptoethanol, 0.5% Penicillin-Streptomycin, 0.3% BSA, 1% ITS-X supplement,
216 2.5 mM Y27632, 2 mM FK, and 4% KnockOut™ Serum Replacement (Thermo Fisher Scientific). To
217 determine the influence of VPA on the expression of syncytialization markers, the TS-medium was
218 removed, and the cells were washed twice with DMEM/F12 to eliminate the TS-medium. The cells
219 were then treated with ST medium containing VPA (0 or 1 mM).

220

221 **2.4. Collection of placental tissue**

222 Human term placentas were donated by 11 women who delivered via a cesarean section. The
223 study participants were pregnant women who were admitted to the Obstetrics Department of Hokkaido
224 University Hospital and met the following criteria: (1) older than or 20 years of age at the time of
225 obtaining consent; (2) delivery by planned cesarean section; and (3) freely gave their consent to
226 participate after receiving sufficient explanation of the study and confirming that they understand the
227 study. Placenta was obtained within 1 h of delivery and used for the experiments. The placental samples
228 obtained from five patients and used for gene expression analyses were the same as those used in a
229 previous study (Hasegawa et al., 2020). The donated placentas were collected at the following
230 gestation times: from 37 weeks 2 days to 39 weeks 1 day. The study comprising human placentas was
231 approved by the Ethics Committee of Hokkaido University Hospital (018-0138).

232

233 2.5. Real-time PCR

234 BeWo cells (2.0×10^5 cells/well) were seeded on 12-well plastic plates and cultured as
235 described in sections 2.2 and 2.3. Total RNA was isolated from BeWo cells and placental villous tissues
236 using ISOGEN II (Nippon Gene, Japan) as previously described (Furugen et al., 2017; Hasegawa et
237 al., 2020). TS^{CT} cells were seeded on Col IV-coated 6-well plastic plates and cultured as described in
238 sections 2.2 and 2.3. Total RNA was extracted using an RNeasy Mini Kit (QIAGEN) in accordance
239 with the manufacturer's protocol. cDNA was synthesized from total RNA (1 µg) via reverse
240 transcription using ReverTra Ace® (TOYOBO, Osaka, Japan).

241 Real-time PCR analysis was conducted using the Mx3000PTM or Mx3005TM Real-time PCR
242 System (STRATAGENE) with the KAPA SYBR® Fast qPCR kit (KAPA Biosystems, Boston). The
243 primers used in this study are listed in Supplemental Table 1. The specificity of primers was assessed
244 using the melting curve analysis and agarose gel electrophoresis (Supplemental Figure 1). The cycling
245 conditions were as follows: 40 cycles at 95 °C for 3 s and 60 °C for 20 s (except for *ASCT2/SLC1A5*),
246 40 cycles at 95 °C for 3 s, and 65 °C for 20 s for *SLC1A5*. The levels of the target genes were
247 normalized to tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta
248 (*YWHAZ*). As shown in Supplemental Figure 2, no substantial changes were noted in Ct values during
249 differentiation. We confirmed that *YWHAZ* was suitable for use as a reference gene, although we
250 could not evaluate all the candidate housekeeping genes in the present study. Data were analyzed by
251 the relative standard curve method (Figure 1, 2, 4A, and Supplemental Figure 3). To investigate the

252 expression levels in BeWo (FK), ST-TS^{CT}, and placenta (Supplemental Figure 5), data were analyzed
253 by the comparative cycle time (Ct) method.

254 **2.6. Enzyme-linked immunosorbent assay**

255 BeWo cells (1.0×10^5 cells/well) were seeded on 24-well plastic plates and cultured as
256 described in sections 2.2 and 2.3. After treatment with FK (20 μ M) and VPA (1 mM) or LTG (50 μ M),
257 the cell culture medium was collected. hCG secretion was measured using an hCG enzyme-linked
258 immunosorbent assay (ELISA) kit (Abcam, Cambridge, UK) as previously described (Koishikawa et
259 al., 2022).

260

261 **2.7. Western blotting**

262 BeWo cells (4.0×10^5 cells/well) were seeded on 6-well plastic plates and cultured as described
263 in sections 2.2 and 2.3. After treatment with FK (20 μ M) and VPA (1 mM), the cells were lysed in ice-
264 cold lysis buffer supplemented with cCompleteTM Mini protease inhibitor cocktail tablets with 1 mM
265 phenylmethylsulfonyl fluoride. Western blotting was performed as previously described (Furugen et
266 al., 2017). The primary antibodies used were rabbit anti-SLC1A5 (1:1,000, Abcam, #ab237704) and
267 mouse anti-actin (1:1000, Chemicon, Temecula, CA, #MAB1501) monoclonal antibodies. The bound
268 proteins were detected using horseradish peroxidase-conjugated secondary antibodies and ECL
269 PrimeTM western blotting Detection Reagent or ECL Western Blotting Detection Reagents (GE
270 Healthcare, Buckinghamshire, England) . The bands were detected using Image Quant LAS 4000 (GE

Healthcare). Band intensities were analyzed using ImageJ software (National Institutes of Health, Bethesda, MD, USA).

2.8. Cell fusion assay

BeWo cells (5.0×10^4 cells/dish) were seeded on collagen-coated glass-bottom dishes and cultured. Thereafter, the cells were treated with FK (20 μ M) and VPA (1 mM) as described in section 2.3. TS^{CT} cells (1.0×10^5 cells/dish) were seeded on Col IV-coated glass-bottom dishes and cultured as described in sections 2.2 and 2.3. After treatment, the cells were washed with phosphate buffer saline (PBS) and fixed in 4% formaldehyde (Thermo Fisher Scientific) for 15 min at room temperature. To prevent non-specific antigen binding, the cells were blocked with 5% goat serum (Abcam) in PBS for 1 h at room temperature. Thereafter, the samples were incubated with rabbit monoclonal anti-E-cadherin antibody (1:100, #3195, Cell Signaling Technology) diluted in antibody dilution buffer (PBS, 1% BSA, 0.3% Triton X-100) overnight at 4 °C, followed by Alexa Fluor® 488-conjugated goat anti-rabbit IgG diluted in an antibody dilution buffer (1:1000, #4412, Cell Signaling Technology) for 1 h in the dark at room temperature. The nuclei were stained with DAPI (Wako) in PBS for 10 min at room temperature in the dark. After staining, the cells were covered with Prolong® Gold Antifade Reagent (Cell Signaling Technology) and stored at 4 °C in the dark until microscopic assessment using FluoView FV10i (Olympus) or BZ-9000 (KEYENCE). Four fields were selected for the analysis. The results were analyzed as previously described (Clabault et al., 2018; Morosin et al., 2021). A syncytium is defined as a cell containing two or more nuclei in the cytoplasm without E-cadherin-stained

290 membranes. The fusion index is the total number of nuclei in the syncytium divided by the total number
291 of nuclei present; the resulting value was converted to a percentage by multiplying by 100.

292 **2.9. MTT assay**

293 Cell viability was investigated using the MTT assay. BeWo cells (2.0×10^4 cells/well) were
294 seeded in 96-well plastic plates. TS^{CT} cells (5.0×10^3 cells/well) were seeded in Col IV-coated 96-well
295 plastic plates. After growth of the cells, VPA was added as described in Section 2.3. Before the end of
296 treatment, 10 μ L of the MTT solution (5 mg/mL in phosphate-buffered saline) was added to the cells.
297 The cells were then incubated for 1 h, and the culture medium was subsequently aspirated. The MTT
298 formazan was dissolved in 200 μ L of DMSO, and the absorbance of solution in each well was read at
299 570 nm.

300

301 **2.10. Statistical analysis**

302 The experiments were repeated at least three times. The data are expressed as mean $\pm$ standard
303 error (S.E.) of independent experiments. Student's t-test was used for comparisons between the two
304 groups while Tukey–Kramer or Dunnett's test was used for multiple comparisons. Correlations
305 between the expression levels of syncytialization markers and neonatal/placental parameters were
306 analyzed using the Spearman's correlation test. Statistical significance was set at $p < 0.05$.

307

308

309

310 3. Results

311 3.1. Screening investigation of the effects of antiepileptic drugs on gene expression associated 312 with syncytialization

313 First, we screened the effects of eight antiepileptic drugs, VPA, CBZ, LTG, GBP, LEV, TPM,
314 LCM, and CLB, on the gene expression of syncytialization markers in FK-induced differentiated
315 BeWo cells. We previously tested the effects of 24-hour exposure of antiepileptic drugs (VPA, CBZ,
316 LTG, GBP, LEV, TPM, LCM, and CLB) on the viability of undifferentiated BeWo cells (Kurosawa et
317 al., 2018). Because these antiepileptic drugs did not affect the viability of undifferentiated BeWo cells,
318 we chose the concentration close to that used in the previous study. In this study, we opted to evaluate
319 syncytin-1 (*ERVW-1*), syncytin-2 (*ERVFRD-1*), connexin-43 (*GJA1*), β -hCG (*CGB*), hPL (*CSH*),
320 ASCT2 (*SLC1A5*), MFSD2 (*MFSD2A*), and MRP4 (*ABCC4*). FK (20 μ M) upregulated the expression
321 of *ERVW-1*, *ERVFRD-1*, and *CGB* (Figure 1A, 1B, and 1E), and downregulated the expression of
322 *GJA1*, *SLC1A5*, *CSH*, and *ABCC4* (Figure 1C, 1D, 1F, and 1G). Exposure to VPA (1 mM) reduced the
323 expression of *ERVW-1*, *ERVFRD-1*, and *CGB* under FK-induced conditions (Figure 1A, 1B, and 1E).
324 *SLC1A5* and *CSH* mRNAs levels were reduced by VPA in both undifferentiated and differentiated cells
325 (Figure 1D and 1F). Exposure to VPA increased the expression of *ABCC4* in both undifferentiated and
326 differentiated conditions (Figure 1G). The decreased *GJA1* expression in differentiated cells tended to
327 be restored by exposure to VPA (Figure 1C). In contrast, exposure to other antiepileptic drugs, such as

328 CBZ, LTG, GBP, LEV, TPM, LCM, and CLB, had no noticeable effect on the expression of these
329 genes. As *MFSD2A* levels were very low in undifferentiated BeWo cells, we did not investigate the
330 effects of the antiepileptic drugs on *MFSD2* expression in this cell line. We also investigated the effects
331 of VPA and LTG on several genes using another reference gene (succinate dehydrogenase complex
332 flavoprotein subunit A, *SDHA*) (Supplemental Figure 3). The trend was similar when the expression
333 levels were normalized against *YWHAZ* or *SDHA*.

334

335 **3.2. Concentration-dependent effect of VPA on gene expression associated with syncytialization**

336 VPA poses several risks to the fetus. Notably, the harmful effects of VPA on fetus, such as
337 teratogenicity and reduced cognitive abilities, have been reported to be dose-dependent (Tomson et al.,
338 2011; Meador et al., 2013). In this study, we investigated the concentration-dependent effect of VPA
339 on gene expression in differentiated BeWo cells. As shown in Figure 2, the effects of VPA on the levels
340 of *ERVW-1*, *ERVFRD-1*, *GJA1*, *CGB*, *CSH*, *SLC1A5*, and *ABCC4* tended to increase with increasing
341 VPA concentration (Figure 2). *GCM1/GCM1*, a transcription factor that regulates the expression of
342 *ERVW-1*, was also investigated in this assessment. *GCM1* was slightly upregulated by FK and
343 suppressed by exposure to VPA (Figure 2D).

344

345 **3.3. Effect of exposure to VPA on protein expression associated with syncytialization**

346 As VPA exposure considerably affected the expression of genes associated with

347 syncytialization in BeWo cells, protein expression after VPA exposure was investigated. Briefly, the
348 protein levels of hCG and ASCT were assessed. Based on ELISA, hCG secretion increased after FK
349 stimulation and was suppressed by exposure to VPA (1 mM) (Figure 3A). We also assessed the effects
350 of LTG on hCG secretion. LTG did not have any significant effect on the mRNA levels of
351 syncytialization markers (Figure 1). As described in the Introduction section, LTG is recommended
352 for women of reproductive-aged with epilepsy. LTG had no significant effect on hCG secretion (Figure
353 3A). Before the effect of VPA on ASCT2 protein levels was determined, the reactivity of the antibody
354 was confirmed by western blotting. The ASCT2 antibody detected two bands, and siRNAs of ASCT2
355 reduced the band detected between 120 and 210 kDa (Supplemental Figure 4). The predicted size of
356 ASCT2 is 75 kDa. Further, ASCT2 forms dimer and trimer (Pingitore et al., 2013). Based on the result,
357 ASCT2 exists as a multimer. The bands were further analyzed. ASCT2 expression was reduced by
358 VPA under differentiated condition (Figure 3B).

359

360 **3.4. Effect of VPA exposure on cell fusion by BeWo cells**

361 The effect of VPA on cell fusion was evaluated using a fusion assay. In this study, E-cadherin,
362 which contributes to cell-cell adhesion, was immunostained (green) and the nuclei were stained with
363 DAPI (blue). The degree of cell fusion was analyzed using the fusion index. As shown in Figure 3C,
364 cells were predominantly mononucleated under unstimulated conditions (control). FK (20 μ M)
365 treatment induced cell fusion, as indicated by the presence of multinucleated syncytia lacking distinct

cell boundaries; the fusion index was significantly higher than that of the control. Exposure to VPA significantly suppressed cell fusion under FK treatment. Overall, VPA induces morphological changes in BeWo cells in addition to altering syncytialization-associated genes.

3.5. Effects of VPA in human trophoblast stem TS^{CT} cells

In the present study, we determined the effects of VPA on gene expression associated with syncytialization using another trophoblast model, human trophoblast stem cells (TS^{CT} cells). Prior to the assay, we investigated the expression levels of genes associated with syncytialization in human term placentas, FK-induced differentiated BeWo cells (BeWo (FK)), TS^{CT} cells, and TS^{CT}-derived ST cells (ST-TS^{CT}) (Supplemental Figure 5). In the present study, we used the villous part of term placenta, which is abundant in syncytiotrophoblasts. The expression levels were normalized against *YWHAZ*. *TBP*, *SDHA*, and *YWHAZ* have been reported to be stable and appropriate for comparative expression studies in placenta (Meller et al., 2005). As shown in Supplemental Table 2, average Ct values were not much different among BeWo cells, TS cells, and term placenta. All markers were detected in both BeWo (FK) and ST-TS^{CT} cells. *ERVW-1* level in ST-TS^{CT} cells was significantly higher than in BeWo (FK) cells. *ERVFRD-1* levels in the placenta and BeWo (FK) cells were comparable; however, its expression was higher in the ST-TS^{CT} cells. *GJA1* expression in the placenta was higher than in the cell lines (BeWo (FK) and ST-TS^{CT} cell). The levels of *GCM1* were comparable between the placental and BeWo (FK) cells. *SLC1A5* levels in BeWo (FK) and ST-TS^{CT} cells were higher than in the placenta.

385 *SLC1A5* levels in BeWo (FK) cells were higher than those in ST-TS^{CT} cells. The expression of
386 *MFSD2A* was high in the placenta and sufficient in ST-TS^{CT} cells. Furthermore, the expression of *CGB*
387 was prominent in ST-TS^{CT} cells, whereas that of *CSH* was comparable between BeWo (FK) and ST-
388 TS^{CT} cells. *ABCC4* levels were comparable among the placenta, BeWo (FK) cells, and ST-TS^{CT} cells.
389 Of note, we could not accurately analyze the expression of *CSH* in the placenta using the current
390 method due to non-specific amplification.

391 As shown in Supplemental Figure 5, cell culture in ST-medium markedly induced the
392 expression of *CGB*, which has been reported to be upregulated in TS^{CT}-derived ST cells (ST-TS^{CT}
393 cells) (Okoe et al., 2018), confirming differentiation. The expression of *ERVW-1* and *ERVFRD-1*
394 increased, whereas that of *ABCC4* decreased in ST-TS^{CT} cells. These results were consistent with those
395 observed in BeWo cells (Figure 1 and 2). The expression of *MFSD2A* in undifferentiated BeWo cells
396 was low (Ct value were approximately 35). Although *MFSD2A* was detected in BeWo (FK) cells, the
397 Ct values were > 30. Meanwhile, the expression of *MFSD2A* was sufficiently detected in ST-TS^{CT} cells
398 (Mean Ct value = 26.2; n = 3). Although the difference was not statistically significant by multiple
399 comparison analysis ($p = 0.1439$), the expression of *CSH* in TS^{CT} cells tended to increase with
400 differentiation, which contradicted the results in BeWo cells (Figure 1F). We proceeded to determine
401 the effects of VPA-containing ST medium on gene expression associated with syncytialization (Figure
402 4A). VPA exposure decreased the expression of *ERVW-1*, *ERVFRD-1*, and *CSH*, and increased that of
403 *GJA1* and *ABCC4*. Although not significant ($p = 0.059$), *CGB* expression tended to decrease after VPA

404 exposure. The effects of VPA on TS^{CT} cells were similar to those observed in BeWo cells. As shown
405 in Figure 4B, the fusion index was significantly increased in ST-TS^{CT} cells compared with that in TS^{CT}
406 cells. Exposure to VPA significantly suppressed cell fusion. The results suggest that VPA also affected
407 syncytialization of TS^{CT}-derived cells. *SLC1A5* and *GCM1* expression was not altered by VPA-
408 containing ST medium. The expression of *MFSD2A*, which was not analyzed in BeWo cells, was
409 decreased by exposure to VPA. Overall, VPA affects the differentiation in human ST cells.

410

411 **3.6. Association between neonatal/placental parameters and expression of genes associated with** 412 **syncytialization in human term placenta**

413 As described in the Introduction section, previous studies have indicated that anomalies in the
414 expression of hormones and syncytialization markers are associated with obstetric complications.
415 However, systematical analyses of relationships between syncytialization-associated genes in placenta
416 and neonatal/placental parameters have not been fully evaluated. Finally, we assessed the correlation
417 between neonatal/placental parameters and expression associated with syncytialization in human term
418 placentas (Figure 5). *MFSD2A* expression level in the placenta was positively correlated with neonatal
419 weight, head circumference, chest circumference, and placental weight (Figure 5F). *ABCC4* levels
420 were negatively correlated with placental weight (Figure 5G). *CGB* levels in the placenta had a
421 negative correlation with neonatal head circumference (Figure 5H). No significant correlation was
422 found between *ERVW-1*, *ERVFRD-1*, *GJA1*, *GCM1*, and *SLC1A5* expression.

423 4. Discussion

424 Most pregnant women with epilepsy must continue taking their medication for seizure
425 management (Tomson et al., 2011). In addition to older antiepileptic drugs, newer antiepileptic drugs,
426 which have more favorable pharmacokinetic profiles and fewer drug interactions, have become
427 available for clinical use (Avachat et al., 2022). Notably, prescription patterns of antiepileptic drugs
428 during pregnancy have changed globally over the past decade (Avachat et al., 2022). For example, the
429 Australian pregnancy register reported a declining trend in the use of VPA and CBZ, which are older
430 antiepileptic drugs (Vajda et al., 2014; Vajda et al., 2019). Based on the outcomes and
431 neurodevelopmental effects of antiepileptic drugs in the USA, LTG and LEV, which are newer
432 antiepileptic drugs, were reported as the most commonly prescribed monotherapies between 2012 and
433 2016 (Meador et al., 2018). In contrast, VPA was the most commonly prescribed antiepileptic drug in
434 Japan between 2005–2016 (Ishikawa et al., 2019). Furthermore, unplanned pregnancy commonly
435 occurs in women with epilepsy (Herzog et al., 2017). To better understand the mechanism of
436 reproductive toxicity induced by antiepileptic drugs and predict the possible risks to the fetus, the
437 effects of multiple drugs, including older and newer ones, must be comprehensively analyzed. Recently,
438 trophoblast functions were reported to be altered by maternal conditions (Le et al., 2014; Clabault et
439 al., 2018; Drwal et al., 2020; Walker et al., 2020; Wang et al., 2021). Therefore, the current study aimed
440 to determine the effects of antiepileptic drugs on the differentiation of human placental trophoblasts.

441 Screening using the BeWo cell line, a trophoblast model, revealed that VPA altered

442 syncytialization-associated genes and cell fusion. In addition, changes in hCG and ASCT2 protein
443 levels were observed. In contrast, exposure to other antiepileptic drugs at clinically relevant
444 concentrations, namely CBZ, LTG, GBP, LEV, TPM, LCM, and CLB, had no significant effect on the
445 expression of syncytialization-associated genes. We confirmed that LTG did not affect the secretion of
446 hCG from BeWo cells. Although we did not evaluate the effects of all antiepileptic drugs in the current
447 study, the results support the notion that gene expression analysis may be useful in predicting the
448 effects of drugs on syncytialization. Further studies are required to evaluate whether antiepileptic drugs
449 other than VPA affect syncytiotrophoblast formation. The risks associated with VPA use during
450 pregnancy, such as teratogenicity, neurodevelopmental delay, and autism spectrum disorder, are widely
451 recognized. However, information on other obstetric complications associated with antiepileptic drug
452 use during pregnancy, particularly fetal growth and placentation, has not been fully elucidated.
453 Previously, we revealed that repeated VPA administration decreased placental weight in Wistar rats
454 (Jinno et al., 2020). VPA concentrations in maternal plasma and umbilical blood have been reported to
455 have an inverse relationship with neonatal body height and weight (Kacirova et al., 2015). The adverse
456 effects of *in utero* exposure to VPA, reduced cognitive abilities, and malformations are dose-dependent
457 (Tomson et al., 2011; Meador et al., 2013). In the present study, the effects of VPA on syncytialization-
458 associated genes were demonstrated to be dose-dependent.

459 Generally used *in vitro* models are isolated primary cultures, placental explants, and
460 trophoblast cell lines (Ji et al., 2013). BeWo is a continuous cell line derived from human placental

461 choriocarcinoma that is widely used for toxicological assessment and investigation of syncytialization
462 (Ji et al., 2013). However, differences in gene expression and responses to various stimuli between
463 cancer cell lines and normal trophoblasts should be considered (Myllynen et al., 2013). The derivation
464 of human trophoblast stem cells from CT cells isolated from human placentas (TS^{CT} cells) has been
465 reported (Okada et al., 2018). In this study, we utilized this cell model for the analyses. The expression
466 of several genes, including *ERVW-1*, *ERVFRD-1*, *CGB*, and *MFSD2A*, was predominant in ST-TS^{CT}
467 compared with BeWo (FK) cells. In particular, *MFSD2A* levels were very low in BeWo; therefore, we
468 could not investigate the effects of antiepileptic drugs on *MFSD2A* expression in cells. Using ST-TS^{CT}
469 cells, we found that VPA downregulated *MFSD2A* levels. When BeWo cells and TS^{CT} cells were
470 compared, the expression patterns of markers during differentiation were found to display similar
471 trends, except for *CSH*. The expression of *CSH* in BeWo cells decreased after differentiation, whereas
472 its expression tended to increase in ST-TS^{CT} cells. The phenomenon observed in BeWo cells was
473 consistent with that found in a previous study (Clabault et al., 2018). *CSH* expression increases during
474 the differentiation of human primary trophoblasts (Handwerger, 2010). Overall, the TS^{CT} model is
475 more suitable for investigating hPL/*CSH* expression and function. With regard to sensitivity to
476 antiepileptic drugs, alteration of the expression of markers by exposure to VPA displayed similar trends,
477 except for *SLC1A5* and *GCM1*. The expression levels of *SLC1A5* and *GCM1* in differentiated BeWo
478 cells were decreased by VPA exposure; however, these effects were not observed in ST-TS^{CT} cells. The
479 fusion assay revealed the effects of VPA exposure on syncytialization in ST-TS^{CT} cells. Because we

480 could not measure protein concentration in the present study, further studies are needed to assess the
481 alterations in protein levels of syncytialization markers. To compare the expression levels of genes
482 associated with syncytialization in placenta and cell lines, we used the villous part of term placenta.
483 Because placental tissue is heterogeneous, trophoblasts isolated from placenta villous need to be
484 analyzed for accurate comparison. Further investigations are required to reveal the effects of VPA on
485 primary trophoblasts and the causes of these differences.

486 VPA affects the biochemistry of folate, which is a key component in nucleotide synthesis and
487 thereby proliferation (Fathe K et al., 2014; Reynolds and Green, 2020). Moreover, VPA, at relatively
488 higher concentrations, exhibits antiproliferative activity in cancer cells (Du et al., 2022). In the study,
489 we chose the concentrations without significant effect on the viability of undifferentiated BeWo cells
490 based on a previous study (Kurosawa et al., 2018). In addition, no effect of VPA doses ranging from
491 0.45 to 1.5 mM on undifferentiated BeWo cells was observed after 24–48 h of exposure (Kwiecińska
492 et al., 2011). However, the effects of antiepileptic drugs on the viability of differentiated cells have not
493 been examined. We investigated the effects of VPA on the viability of differentiated BeWo or TS cells
494 using the MTT assay. As shown in Supplemental Figure 6, the viability of differentiated BeWo cells
495 was not significantly affected upon treatment with 1 mM VPA. However, the proliferation of ST-TS^{CT}
496 cells was reduced compared with that of TS^{CT} cells. Exposure to VPA restored the proliferation of ST-
497 TS^{CT} cells. These differences may be due to the cell type (cancerous or normal cells). On the contrary,
498 alterations in the expression of differentiation markers upon VPA exposure displayed similar trends in

499 differentiated BeWo cells and ST-TS^{CT} cells. Although we could not completely exclude the possibility
500 that cell proliferation subsequently affects differentiation markers, these observations suggest that the
501 effects of VPA on these markers are independent of alterations in cell proliferation. In the present and
502 previous study (Kurosawa et al., 2018), we assessed cell viability by only MTT assay at single time
503 point. Although the MTT assay is widely used for the assessment of cytotoxicity, cell viability, and
504 proliferation, the data obtained by this assay should be interpreted with caution (Stockert et al., 2012).
505 Furthermore, the present study could not address whether cell proliferation (doubling and growth) was
506 affected by exposure to antiepileptic drugs. Future studies are required to evaluate the detailed effects
507 of VPA and other antiepileptic drugs on cytotoxicity and cell proliferation using various approaches
508 (e.g., LDH assay, thymidine incorporation assay, and real-time cell analysis).

509 Placental microenvironment has been reported to exhibit severe hypoxic conditions,
510 especially in the first trimester (Zhao et al., 2021). Furthermore, O₂ levels affect the differentiation of
511 cytotrophoblast into syncytiotrophoblast (Zhao et al., 2021). In the present study, cells were cultured
512 under normal O₂ conditions. Future studies should investigate the effects of antiepileptic drugs on
513 differentiation under hypoxic conditions.

514 In the present study, we analyzed the relationship between neonatal/placental parameters and
515 gene expression associated with syncytialization in human term placentas. *MFSD2A* was found to be
516 positively correlated with several parameters (neonatal body weight, head circumference, chest
517 circumference, and placental weight). *MFSD2/MFSD2A* is the receptor for syncytin-2 and has been

518 reported to play an important role in ST development in the human placenta (Esnault et al., 2008).
519 Further, MFSD2 expression in the placenta decreases obstetric complications, such as fetal growth
520 restriction and gestational diabetic (Ruebner et al., 2010; Soygur et al., 2016). In this study, VPA
521 downregulated *MFSD2A* mRNA in ST-TS^{CT} cells. Placenta-derived nucleic acids in maternal plasma
522 can be used to predict pregnancy-related complications (Manokhina et al., 2005). These observations
523 suggest that *MFSD2A* can be used as a biomarker to predict fetal and placental toxicity of drugs.
524 Because we obtained RNA samples for gene analyses in the present study, protein levels of
525 syncytialization markers, including MFSD2, were not evaluated. Further studies are required to
526 evaluate the association between MFSD2 protein levels and neonatal/placental parameters, and
527 MFSD2/*MFSD2A* expression in placenta donated by women treated with antiepileptic drugs.

528 In summary, the current study was conducted to comprehensively investigate the effects of
529 eight antiepileptic drugs on syncytialization-associated genes in the BeWo human trophoblast cell line.
530 VPA was found to have a dose-dependent effect on alterations in gene expression accompanied by
531 differentiation. VPA also suppressed the fusion of BeWo and TS^{CT} cells. The present findings suggest
532 that TS^{CT} cells are useful as trophoblast models for toxicological research to investigate drug-induced
533 alterations of syncytialization. In addition, our study implied that *MFSD2A* expression in term
534 placentas is positively correlated with several neonatal/placental parameters. This study had some
535 limitations. First, we did not analyze the effects of VPA on primary trophoblasts or *in vivo*. The
536 differences between the experimental models and the extrapolation of results obtained using the cell

537 lines to real trophoblasts must be performed with caution. Second, for the analysis of syncytialization
538 markers in the placenta, we could not precisely unify patient characteristics. Further, the sample
539 number of the placenta was relatively low for accurate analysis. Third, we did not explore the
540 underlying mechanisms of reduced syncytialization following VPA exposure. As mentioned in the
541 Introduction section, VPA exhibits inhibitory effects on HDACs (Gurvich et al., 2004), which are
542 involved in the regulation of gene expression. Because HDAC inhibitors impair human
543 syncytiotrophoblast formation (Jaju Bhattad et al., 2020), the present results of VPA affecting the
544 differentiation of BeWo and TS^{CT} cells are reasonable. However, other antiepileptic drugs, namely
545 CBZ, TPM, and LCM, that altered the HDAC activity did not have significant effect on
546 syncytialization-associated genes in BeWo cells. Further studies are required to evaluate the
547 involvement of HDACs in syncytialization of cells exposed to antiepileptic drugs. Furthermore,
548 various signaling pathways are reported to be involved in the syncytialization process (Gupta et al.,
549 2016). Future studies should address these issues to enable a more robust examination of the
550 mechanism of VPA toxicity and estimate the risk of obstetric complications.

551

552 **Funding**

553 This work was supported in part by a grant from the Japan Society for the Promotion of
554 Science (JSPS) KAKENHI (grant number 20K0714900) (to A.F.).

555

556 **Acknowledgments**

557 We thank Ms. Haruna Kosugi for her research assistance.

558

559 **Author contributions**

560 **Nanami Ohyama:** Conceptualization, Investigation, Formal analysis, Writing - original draft

561 **Ayako Furugen:** Conceptualization, Investigation, Formal analysis, Writing - original draft

562 **Riko Sawada:** Investigation, Writing - review & editing.

563 **Ryoichi Aoyagi:** Investigation, Writing - review & editing.

564 **Ayako Nishimura:** Resources, Writing - review & editing.

565 **Takeshi Umazume:** Resources, Writing - review & editing.

566 **Katsuya Narumi:** Writing - review & editing.

567 **Masaki Kobayashi:** Supervision, Writing - review & editing.

568

569 **Conflicts of Interest**

570 The authors report no conflicts of interest.

References

- Avachat, C., Barry, J. M., Lyu, X., Sherwin, C. M., Birnbaum, A. K., 2022. Management of Anti-Seizure Medications during Pregnancy: Advancements in The Past Decade. *Pharmaceutics*. 14, 2733. <https://doi.org/10.3390/pharmaceutics14122733>
- Bang, S.R., Ambavade, S.D., Jagdale, P.G., Adkar, P.P., Waghmare, A.B., Ambavade, P.D., 2015. Lacosamide reduces HDAC levels in the brain and improves memory: Potential for treatment of Alzheimer's disease. *Pharmacol. Biochem. Behav.* 134:65-69. <https://doi.org/10.1016/j.pbb.2015.04.011>.
- Beutler, A.S., Li, S., Nicol, R., Walsh, M.J., 2005. Carbamazepine is an inhibitor of histone deacetylases. *Life Sci.* 76:3107-3115. <https://doi.org/10.1016/j.lfs.2005.01.003>.
- Chen, C. P., Wang, K. G., Chen, C. Y., Yu, C., Chuang, H. C., Chen, H., 2006. Altered placental syncytin and its receptor ASCT2 expression in placental development and pre-eclampsia. *BJOG*. 113:152-158. <https://doi.org/10.1111/j.1471-0528.2005.00843.x>
- Christensen, J., Grønborg, T.K., Sørensen, M.J., Schendel, D., Partner, E.T., Pedersen, L.H., 2013. Vestergaard M. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. *JAMA*. 309:1696-1703. <https://doi.org/10.1001/jama.2013.2270>.
- Clabault, H., Flipo, D., Guibourdenche, J., Fournier, T., Sanderson, J. T., Vaillancourt, C., 2018. Effects of selective serotonin-reuptake inhibitors (SSRIs) on human villous trophoblasts syncytialization. *Toxicol. Appl. Pharmacol.* 349:8-20. <https://doi.org/10.1016/j.taap.2018.04.018>
- Copsel, S., Garcia, C., Diez, F., Vermeulem, M., Baldi, A., Bianciotti, L. G., Russel, F. G., Shayo, C., & Davio, C., 2011. Multidrug resistance protein 4 (MRP4/ABCC4) regulates cAMP cellular levels and controls human leukemia cell proliferation and differentiation. *J. Biol. Chem.* 286:6979-6988. <https://doi.org/10.1074/jbc.M110.166868>
- Costa, M.A., 2016. The endocrine function of human placenta: an overview. *Reprod. Biomed. Online*. 32:14-43. <https://doi.org/10.1016/j.rbmo.2015.10.005>
- Drwal, E., Rak, A., Tworzydło, W., Gregoraszczuk, E. Ł., 2020. "Real life" polycyclic aromatic hydrocarbon (PAH) mixtures modulate hCG, hPL and hPLGF levels and disrupt the physiological ratio of MMP-2 to MMP-9 and VEGF expression in human placenta cell lines. *Reprod. Toxicol.* 95:1-10. <https://doi.org/10.1016/j.reprotox.2020.02.006>

608

609 Du, S., Wang, X., Hu, Y., Zhang, S., Wang, D., Zhang, Q., Liu, S., 2022. Valproic acid regulates MIEF1
610 through MST2-HIPPO to suppress breast cancer growth. *Life Sci.* 15;309:120976.
611 <https://doi.org/10.1016/j.lfs.2022.120976>.

612

613 Esnault, C., Priet, S., Ribet, D., Vernochet, C., Bruls, T., Lavialle, C., Weissenbach, J., Heidmann, T.,
614 2008. A placenta-specific receptor for the fusogenic, endogenous retrovirus-derived, human syncytin-
615 2. *Proc. Natl. Acad. Sci. U S A.*105: 17532–17537. <https://doi.org/10.1073/pnas.0807413105>

616

617 Eyal, S., Yagen, B., Sobol, E., Altschuler, Y., Shmuel, M., Bialer, M., 2004. The activity of antiepileptic
618 drugs as histone deacetylase inhibitors. *Epilepsia.* 45:737-744. [https://doi.org/10.1111/j.0013-](https://doi.org/10.1111/j.0013-9580.2004.00104.x)
619 9580.2004.00104.x.

620

621 Fathe, K., Palacios, A., Finnell, R.H., 2014. Brief report novel mechanism for valproate-induced
622 teratogenicity. *Birth Defects Res. A Clin. Mol. Teratol.* 100:592-597.
623 <https://doi.org/10.1002/bdra.23277>.

624

625 Frendo, J. L., Cronier, L., Bertin, G., Guibourdenche, J., Vidaud, M., Evain-Brion, D., Malassine, A.,
626 2003. Involvement of connexin 43 in human trophoblast cell fusion and differentiation. *J. Cell Sci.*
627 116:3413-3421. <https://doi.org/10.1242/jcs.00648>

628

629 Furugen, A., Ishiguro, Y., Kobayashi, M., Narumi, K., Nishimura, A., Hirano, T., Iseki, K., 2017.
630 Involvement of l-type amino acid transporter 1 in the transport of gabapentin into human placental
631 choriocarcinoma cells. *Reprod. Toxicol.* 67:48-55. <https://doi.org/10.1016/j.reprotox.2016.11.002>

632

633 Granit, A., Tetro, N., Shmuel, M., Peretz, T., Eyal, S., 2018. Lacosamide at therapeutic concentrations
634 induces histone hyperacetylation in vitro. *Epilepsia Open.* 3:535-539.
635 <https://doi.org/10.1002/epi4.12269>.

636

637 Gupta, S.K., Malhotra, S.S., Malik, A., Verma, S., Chaudhary, P., 2016. Cell Signaling Pathways
638 Involved During Invasion and Syncytialization of Trophoblast Cells. *Am. J. Reprod. Immunol.* 75:361-
639 371. <https://doi.org/10.1111/aji.12436>

640

641 Handwerger S., 2010. New insights into the regulation of human cytotrophoblast cell
642 differentiation. *Mol. Cell Endocrinol.* 323:94-104. <https://doi.org/10.1016/j.mce.2009.12.015>

643

644 Hasegawa, N., Furugen, A., Ono, K., Koishikawa, M., Miyazawa, Y., Nishimura, A., Umazume, T.,
645 Narumi, K., Kobayashi, M., Iseki, K., 2020. Cellular uptake properties of lamotrigine in human

placental cell lines: Investigation of involvement of organic cation transporters (SLC22A1-5). *Drug Metab. Pharmacokinet.* 35:266-273. <https://doi.org/10.1016/j.dmpk.2020.01.005>

Hernandez-Diaz, S., Huybrechts, K.F., Desai, R.J., Cohen, J.M., Mogun, H., Pennell, P.B., Bateman, B.T., Paterno, E., 2018. Topiramate use early in pregnancy and the risk of oral clefts: A pregnancy cohort study. *Neurology.* 90:e342-e351. <https://doi.org/10.1212/WNL.0000000000004857>.

Herzog, A. G., Mandle, H. B., Cahill, K. E., Fowler, K. M., Hauser, W. A., 2017. Predictors of unintended pregnancy in women with epilepsy. *Neurology.*;88:728-733. <https://doi.org/10.1212/WNL.0000000000003637>

Hoeltzenbein, M., Slimi, S., Fietz, A.K., Stegherr, R., Onken, M., Beyersmann, J., Dathe, K., Schaefer, C., 2023. Increasing use of newer antiseizure medication during pregnancy: An observational study with special focus on lacosamide. *Seizure.* 107:107-113. <https://doi.org/10.1016/j.seizure.2023.02.015>.

Huang, Q., Chen, H., Li, J., Oliver, M., Ma, X., Byck, D., Gao, Y., Jiang, S. W., 2014. Epigenetic and non-epigenetic regulation of syncytin-1 expression in human placenta and cancer tissues. *Cell Signal.* 26:648-656. <https://doi.org/10.1016/j.cellsig.2013.11.002>

Hurault-Delarue, C., Morris, J.K., Charlton, R., Gini, R., Loane, M., Pierini, A., Puccini, A., Neville, A., Snowball, J., Damase-Michel, C.; EUROMediSAFE consortium., 2019. Prescription of antiepileptic medicines including valproate in pregnant women: A study in three European countries. *Pharmacoepidemiol. Drug Saf.* 28:1510-1518. <https://doi.org/10.1002/pds.4897>.

Ishikawa, T., Obara, T., Jin, K., Nishigori, H., Miyakoda, K., Suzuka, M., Ikeda-Sakai, Y., Akazawa, M., Nakasato, N., Yaegashi, N., Kuriyama, S., Mano, N., 2019. Examination of the prescription of antiepileptic drugs to prenatal and postpartum women in Japan from a health administrative database. *Pharmacoepidemiol. Drug Saf.* 28:804-811. <https://doi.org/10.1002/pds.4749>

Jacob, S., Nair, A. B., 2016. An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic Drugs. *Drugs R. D.* 16:303-316. <https://doi.org/10.1007/s40268-016-0148-6>

Jaju, Bhattad, G., Jeyarajah, M.J., McGill, M.G., Dumeaux, V., Okae, H., Arima, T., Lajoie, P., Bérubé, N.G., Renaud, S.J., 2020. Histone deacetylase 1 and 2 drive differentiation and fusion of progenitor cells in human placental trophoblasts. *Cell Death Dis.* 11:311. <https://doi.org/10.1038/s41419-020-2500-6>.

684 Ji, L., Brkić, J., Liu, M., Fu, G., Peng, C., Wang, Y. L., 2013. Placental trophoblast cell differentiation:
685 physiological regulation and pathological relevance to preeclampsia. *Mol. Aspects Med.* 34, 981–1023.
686 <https://doi.org/10.1016/j.mam.2012.12.008>
687

688 Jinno, N., Furugen, A., Kurosawa, Y., Kanno, Y., Narumi, K., Kobayashi, M., Iseki, K., 2020. Effects
689 of single and repetitive valproic acid administration on the gene expression of placental transporters
690 in pregnant rats: An analysis by gestational period. *Reprod. Toxicol.* 96:47-56.
691 <https://doi.org/10.1016/j.reprotox.2020.04.077>
692

693 Kacirova, I., Grundmann, M., & Brozmanova, H., 2015. Serum levels of valproic acid during delivery
694 in mothers and in umbilical cord - correlation with birth length and weight. *Biomed. Pap. Med. Fac.*
695 *Univ. Palacky. Olomouc. Czech. Repub.* 159:569-575. <https://doi.org/10.5507/bp.2015.055>
696

697 Kim, H., Faught, E., Thurman, D.J., Fishman, J., Kalilani, L., 2019. Antiepileptic Drug Treatment
698 Patterns in Women of Childbearing Age With Epilepsy. *JAMA Neurol.* 76:783-790.
699 <https://doi.org/10.1001/jamaneurol.2019.0447>.
700

701 Knerr, I., Beinder, E., & Rascher, W., 2002. Syncytin, a novel human endogenous retroviral gene in
702 human placenta: evidence for its dysregulation in preeclampsia and HELLP syndrome. *Am. J. Obstet.*
703 *Gynecol.* 186:210-213. <https://doi.org/10.1067/mob.2002.119636>
704

705 Koishikawa, M., Furugen, A., Ohyama, N., Narumi, K., Ishikawa, S., Kobayashi, M., 2022. Uptake of
706 antiepileptic drugs in forskolin-induced differentiated BeWo cells: alteration of gabapentin
707 transport. *Xenobiotica.* 52:405-412. <https://doi.org/10.1080/00498254.2022.2085635>
708

709 Kurosawa, Y., Furugen, A., Nishimura, A., Narumi, K., Kobayashi, M., Iseki, K., 2018. Evaluation of
710 the effects of antiepileptic drugs on folic acid uptake by human placental choriocarcinoma
711 cells. *Toxicol. In Vitro.* 48:104-110. <https://doi.org/10.1016/j.tiv.2017.12.003>
712

713 Kwiecińska, P., Wiśniewska, J., Gregoraszczyk, E. Ł., 2011. Effects of valproic acid (VPA) and
714 levetiracetam (LEV) on proliferation, apoptosis and hormone secretion of the human choriocarcinoma
715 BeWo cell line. *Pharmacol. Rep.* 63:1195-1202. [https://doi.org/10.1016/s1734-1140\(11\)70639-9](https://doi.org/10.1016/s1734-1140(11)70639-9)
716

717 Langbein, M., Strick, R., Strissel, P. L., Vogt, N., Parsch, H., Beckmann, M. W., Schild, R. L., 2008.
718 Impaired cytotrophoblast cell-cell fusion is associated with reduced Syncytin and increased apoptosis
719 in patients with placental dysfunction. *Mol. Reprod. Dev.* 75:175-183.
720 <https://doi.org/10.1002/mrd.20729>
721

722 Lavillette, D., Marin, M., Ruggieri, A., Mallet, F., Cosset, F. L., Kabat, D., 2002. The envelope
 723 glycoprotein of human endogenous retrovirus type W uses a divergent family of amino acid
 724 transporters/cell surface receptors. *J. Virol.* 76:6442-6452. [https://doi.org/10.1128/jvi.76.13.6442-](https://doi.org/10.1128/jvi.76.13.6442-6452.2002)
 725 6452.2002
 726
 727 Lee, X., Keith, J. C., Jr, Stumm, N., Moutsatsos, I., McCoy, J. M., Crum, C. P., Genest, D., Chin, D.,
 728 Ehrenfels, C., Pijnenborg, R., van Assche, F. A., Mi, S., 2001. Downregulation of placental syncytin
 729 expression and abnormal protein localization in pre-eclampsia. *Placenta.* 22:808-812.
 730 <https://doi.org/10.1053/plac.2001.0722>
 731
 732 Le Vee, M., Kolasa, E., Jouan, E., Collet, N., Fardel, O., 2014. Differentiation of human placental
 733 BeWo cells by the environmental contaminant benzo(a)pyrene. *Chem. Biol. Interact.* 210:1-11.
 734 <https://doi.org/10.1016/j.cbi.2013.12.004>
 735
 736 Maltepe, E., Krampitz, G.W., Okazaki, K.M., Red-Horse, K., Mak, W., Simon, M.C., Fisher, S.J., 2005.
 737 Hypoxia-inducible factor-dependent histone deacetylase activity determines stem cell fate in the
 738 placenta. *Development.* 132:3393-3403. <https://doi.org/10.1242/dev.01923>.
 739
 740 Manokhina, I., Wilson, S.L., Robinson, W.P., 2015. Noninvasive nucleic acid-based approaches to
 741 monitor placental health and predict pregnancy-related complications. *Am. J. Obstet. Gynecol.*
 742 213:S197-206. <https://doi.org/10.1016/j.ajog.2015.07.010>.
 743
 744 Meador, K. J., Baker, G. A., Browning, N., Cohen, M. J., Bromley, R. L., Clayton-Smith, J., Kalayjian,
 745 L. A., Kanner, A., Liporace, J. D., Pennell, P. B., Privitera, M., Loring, D. W., NEAD Study Group,
 746 2013. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a
 747 prospective observational study. *Lancet Neurol.* 12:244-252. [https://doi.org/10.1016/S1474-](https://doi.org/10.1016/S1474-4422(12)70323-X)
 748 4422(12)70323-X
 749
 750 Meador, K.J., Loring, D.W., 2016. Developmental effects of antiepileptic drugs and the need for
 751 improved regulations. *Neurology.* 86:297-306. <https://doi.org/10.1212/WNL.0000000000002119>.
 752
 753 Meador, K. J., Pennell, P. B., May, R. C., Gerard, E., Kalayjian, L., Velez-Ruiz, N., Penovich, P., Cavitt,
 754 J., French, J., Hwang, S., Pack, A. M., Sam, M., Moore, E., Ippolito, D. M., & MONEAD Investigator
 755 Group., 2018. Changes in antiepileptic drug-prescribing patterns in pregnant women with
 756 epilepsy. *Epilepsy Behav.* 84:10-14. <https://doi.org/10.1016/j.yebeh.2018.04.009>
 757
 758 Meller, M., Vadachkoria, S., Luthy, D.A., Williams, M.A., 2005. Evaluation of housekeeping genes in
 759 placental comparative expression studies. *Placenta.* 26:601-607.

760 <https://doi.org/10.1016/j.placenta.2004.09.009>.

761

762 Milazzo, G., Mercatelli, D., Di Muzio, G., Triboli, L., De Rosa, P., Perini, G., Giorgi, F.M., 2020.
763 Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and
764 Pharmacological Actionability. *Genes (Basel)*. 11:556. <https://doi.org/10.3390/genes11050556>.

765

766 Morosin, S. K., Delforce, S. J., Kahl, R. G. S., Corbisier de Meaultsart, C., Lumbers, E. R., Pringle, K.
767 G., 2021. The (pro)renin receptor and soluble (pro)renin receptor in choriocarcinoma. *Reproduction*.
768 162:375-384. <https://doi.org/10.1530/REP-20-0650>

769

770 Myllynen, P., Vähäkangas, K., 2013. Placental transfer and metabolism: an overview of the
771 experimental models utilizing human placental tissue. *Toxicol. In Vitro*. 27:507-512.
772 <https://doi.org/10.1016/j.tiv.2012.08.027>

773

774 Okae, H., Toh, H., Sato, T., Hiura, H., Takahashi, S., Shirane, K., Kabayama, Y., Suyama, M., Sasaki,
775 H., Arima, T., 2018. Derivation of Human Trophoblast Stem Cells. *Cell Stem. Cell*. 22:50-63.e6.
776 <https://doi.org/10.1016/j.stem.2017.11.004>

777

778 Okahara, G., Matsubara, S., Oda, T., Sugimoto, J., Jinno, Y., Kanaya, F., 2004. Expression analyses of
779 human endogenous retroviruses (HERVs): tissue-specific and developmental stage-dependent
780 expression of HERVs. *Genomics*. 84:982-990. <https://doi.org/10.1016/j.ygeno.2004.09.004>

781

782 Otto, T., Gellhaus, A., Lüschen, N., Scheidler, J., Bendix, I., Dunk, C., Wolf, N., Lennartz, K.,
783 Köninger, A., Schmidt, M., Kimmig, R., Fandrey, J., Winterhager, E., 2015. Oxygen Sensitivity of
784 Placental Trophoblast Connexins 43 and 46: A Role in Preeclampsia?. *J. Cell. Biochem*. 116:2924-
785 2937. <https://doi.org/10.1002/jcb.25240>

786

787 Pan, Z., Sikandar, S., Witherspoon, M., Dizon, D., Nguyen, T., Benirschke, K., Wiley, C., Vrana, P.,
788 Lipkin, S.M., 2008. Impaired placental trophoblast lineage differentiation in Alkbh1(-/-) mice. *Dev*.
789 *Dyn*. 237:316-327. <https://doi.org/10.1002/dvdy.21418>.

790

791 Patsalos, P.N., Spencer, E.P., Berry, D.J., 2018. Therapeutic drug monitoring of antiepileptic drugs in
792 epilepsy: a 2018 update. *Ther. Drug Monit*. 40:526-548.
793 <https://doi.org/10.1097/FTD.0000000000000546>.

794

795 Pennell, P.B., 2018. Prescribing antiepileptic drugs to women of reproductive age. *Lancet Neurol*.
796 17(6):485-486. [https://doi.org/10.1016/S1474-4422\(18\)30154-6](https://doi.org/10.1016/S1474-4422(18)30154-6).

797

798

799 Pingitore, P., Pochini, L., Scalise, M., Galluccio, M., Hedfalk, K., Indiveri, C., 2013. Large scale
800 production of the active human ASCT2 (SLC1A5) transporter in *Pichia pastoris*--functional and
801 kinetic asymmetry revealed in proteoliposomes. *Biochim. Biophys. Acta.* 1828:2238-2246.
802 <https://doi.org/10.1016/j.bbamem.2013.05.034>

803

804 Reynolds, E.H., Green, R., 2020. Valproate and folate: Congenital and developmental risks. *Epilepsy*
805 *Behav.* 108:107068. <https://doi.org/10.1016/j.yebeh.2020.107068>.

806

807 Ruebner, M., Strissel, P. L., Langbein, M., Fahlbusch, F., Wachter, D. L., Faschingbauer, F., Beckmann,
808 M. W., & Strick, R., 2010. Impaired cell fusion and differentiation in placentae from patients with
809 intrauterine growth restriction correlate with reduced levels of HERV envelope genes. *J. Mol. Med*
810 *(Berl)*. 88:1143-1156. <https://doi.org/10.1007/s00109-010-0656-8>

811

812 Soygur, B., Sati, L., Demir, R., 2016. Altered expression of human endogenous retroviruses syncytin-
813 1, syncytin-2 and their receptors in human normal and gestational diabetic placenta. *Histol.*
814 *Histopathol.* 31:1037-1047. <https://doi.org/10.14670/HH-11-735>

815

816 Stockert, J.C., Blázquez-Castro, A., Cañete, M., Horobin, R.W., Villanueva, A., 2012. MTT assay for
817 cell viability: Intracellular localization of the formazan product is in lipid droplets. *Acta. Histochem.*
818 114:785-796. <https://doi.org/10.1016/j.acthis.2012.01.006>.

819

820 Sztajnkrzyer, M.D., 2002. Valproic acid toxicity: overview and management. *J. Toxicol Clin. Toxicol.*
821 40:789-801. <https://doi.org/10.1081/clt-120014645>.

822

823 Thomas, S.V., Jose, M., Divakaran, S., Sankara, Sarma, P., 2017. Malformation risk of antiepileptic
824 drug exposure during pregnancy in women with epilepsy: Results from a pregnancy registry in South
825 India. *Epilepsia.* 58:274-281. <https://doi.org/10.1111/epi.13632>.

826

827 Tomson, T., Battino, D., Bonizzoni, E., Craig, J., Lindhout, D., Perucca, E., Sabers, A., Thomas S.V.,
828 Vajda, F, EURAP Study Group., 2018. Comparative risk of major congenital malformations with eight
829 different antiepileptic drugs: a prospective cohort study of the EURAP registry. *Lancet Neurol.* 17:530-
830 538. [https://doi.org/10.1016/S1474-4422\(18\)30107-8](https://doi.org/10.1016/S1474-4422(18)30107-8).

831

832 Tomson, T., Battino, D., Bonizzoni, E., Craig, J., Lindhout, D., Sabers, A., Perucca, E., Vajda, F.,
833 EURAP study group, 2011. Dose-dependent risk of malformations with antiepileptic drugs: an analysis
834 of data from the EURAP epilepsy and pregnancy registry. *Lancet Neurol.* 10:609-617.
835 [https://doi.org/10.1016/S1474-4422\(11\)70107-7](https://doi.org/10.1016/S1474-4422(11)70107-7)

836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873

Vajda, F. J., O'Brien, T., Lander, C., Graham, J., Eadie, M., 2014. The efficacy of the newer antiepileptic drugs in controlling seizures in pregnancy. *Epilepsia*.55:1229-1234. <https://doi.org/10.1111/epi.12711>

Vajda, F. J. E., Graham, J. E., Hitchcock, A. A., Lander, C. M., O'Brien, T. J., Eadie, M. J., 2019. Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. *Seizure*. 65:6-11. <https://doi.org/10.1016/j.seizure.2018.12.006>

Walker, O. S., Ragos, R., Gurm, H., Lapierre, M., May, L. L., Raha, S., 2020. Delta-9-tetrahydrocannabinol disrupts mitochondrial function and attenuates syncytialization in human placental BeWo cells. *Physiol. Rep.* 8:e14476. <https://doi.org/10.14814/phy2.14476>

Wang, H. L., Liang, N., Huang, D. X., Zhao, X. Y., Dang, Q. Y., Jiang, X. Y., Xiao, R., Yu, H. L., 2021. The effects of high-density lipoprotein and oxidized high-density lipoprotein on forskolin-induced syncytialization of BeWo cells. *Placenta*. 103:199-205. <https://doi.org/10.1016/j.placenta.2020.10.024>

Zhao, H., Wong, R.J., Stevenson, D.K., 2021. The Impact of Hypoxia in Early Pregnancy on Placental Cells. *Int. J. Mol. Sci.* 22:9675. <https://doi.org/10.3390/ijms22189675>.

874 **Figure captions**

875 **Figure 1.** Effects of antiepileptic drugs on the mRNA level of *ERVW-1* (A), *ERVFRD-1* (B), *GJA1*
876 (C), *SLC1A5* (D), *CGB* (E), *CSH* (F), and *ABCC4* (G) in BeWo cells. After 2 days of culture, BeWo
877 cells were exposed to valproic acid (VPA, 1 mM), carbamazepine (CBZ, 50 μ M), lamotrigine (LTG,
878 50 μ M), gabapentin (GBP, 100 μ M), levetiracetam (LEV, 270 μ M), topiramate (TPM, 50 μ M),
879 lacosamide (LCM, 40 μ M), and clobazam (CLB, 1 μ M) in the presence or absence of 20 μ M forskolin
880 (FK) for 48 h. The mRNA expression levels were determined using real-time PCR. Data are presented
881 as mean with standard error (S.E.) for three independent experiments, each performed in duplicate or
882 triplicate. * p < 0.05, ** p < 0.01 compared with the control. $^{\dagger}p$ < 0.05, $^{\dagger\dagger}p$ < 0.01 compared to FK alone.

883

884 **Figure 2.** The concentration-dependent effects of valproic acid (VPA) on the mRNA level of *ERVW-*
885 *1* (A), *ERVFRD-1* (B), *GJA1* (C), *GCM1* (D), *CGB* (E), *CSH* (F), *SLC1A5* (G), and *ABCC4* (H) in
886 BeWo cells. After 2 days of culture, BeWo cells were exposed to VPA (0 -1000 μ M) with 20 μ M
887 forskolin (FK) for 48 h. These mRNA expression levels were then determined using real-time PCR.
888 Data are presented as mean with standard error (S.E.) for three independent experiments, each
889 performed in duplicate or triplicate. ** p < 0.01 compared with the control. $^{\dagger}p$ < 0.05, $^{\dagger\dagger}p$ < 0.01
890 compared to FK alone.

891

892 **Figure 3.** Effects of valproic acid (VPA) on human chorionic gonadotropin (hCG) secretion (A),

alanine serine cysteine transporter 2 (ASCT2) protein expression (B), and fusion of BeWo cells.

(A) After 2 days of culture, BeWo cells were exposed to culture medium containing VPA (1 mM) or LTG (50 μ M) in the presence or absence of forskolin (FK, 20 μ M) for 48 h. After treatment, hCG concentration in the culture medium was quantified using enzyme-linked immunosorbent assay (ELISA). Data are presented as mean with standard error (S.E.) for three independent experiments, each performed in triplicate. $^{**}p < 0.01$ compared with the control. $^{\dagger\dagger}p < 0.01$ compared with the FK alone treatment.

(B) After 2 days of culture, BeWo cells were exposed to culture medium containing VPA (1 mM) in the presence or absence of forskolin (FK, 20 μ M) for 48 h. ASCT expression in BeWo cells was detected using western blotting. Uncropped blots are shown in Supplemental Figure 4B. Data are presented as mean with standard error (S.E.) for three independent experiments. $^{*}p < 0.05$ compared with the control. $^{\dagger}p < 0.05$ compared with the FK alone treatment.

(C) After 2 days of culture, BeWo cells were exposed to culture medium containing VPA (1 mM) in the presence or absence of forskolin (FK, 20 μ M) for 48 h. (Left) Representative immunofluorescence images; cells were fixed in 4% formaldehyde, stained with E-cadherin (green), counterstained with DAPI for nuclei (blue), and observed under a microscope. The scale bars indicate 50 μ m. (Right) The cellular fusion index was determined by counting nuclei (four images/dish); the index is expressed as the percentage of nuclei in syncytia. Mean with S.E. of three independent experiments. $^{**}p < 0.01$ compared with the control. $^{\dagger\dagger}p < 0.01$ compared with the FK alone treatment.

912 **Figure 4.** Analyses of human trophoblast stem cells.

913 (A) Effects of valproic acid (VPA) on the mRNA level of *ERVW-1*, *ERVFRD-1*, *GJA1*, *GCM1*, *CGB*,
914 *CSH*, *SLC1A5*, *MFSD2A*, and *ABCC4* in ST-TS^{CT} cells. After TS^{CT} cells were cultured for 3 days in
915 TS-medium, the cells were exposed to differentiation medium (ST-medium) containing VPA (1 mM)
916 for 72 h. The mRNA expression levels were determined via real-time PCR. Data are presented as mean
917 with standard error (S.E.) for three independent experiments, each performed in duplicate or triplicate.
918 * $p < 0.05$, ** $p < 0.01$ compared with the control.

919 (B) Effects of valproic acid (VPA) on the fusion of TS cells. After TS^{CT} cells were cultured for 3 days
920 in TS-medium, the cells were exposed to differentiation medium (ST-medium) containing VPA (1 mM)
921 for 72 h. (Left) Representative immunofluorescence images; cells were fixed in 4% formaldehyde,
922 stained with E-cadherin (green), counterstained with DAPI for nuclei (blue), and observed under a
923 microscope. The scale bars indicate 50 μm . The cellular fusion index was determined by counting
924 nuclei (four images/dish); the index is expressed as the percentage of nuclei in syncytia. Mean with
925 S.E. of three independent experiments. ** $p < 0.01$ compared with the TS^{CT}. †† $p < 0.01$ compared with
926 ST-TS^{CT}.

927

928 **Figure 5.** Correlations between the expression levels of the syncytialization markers (*ERVW-1* (A),
929 *ERVFRD-1* (B), *GJA1* (C), *GCM1* (D), *SLC1A5* (E), *MFSD2A* (F), *ABCC4* (G), and *CGB* (H)) and
930 neonatal/ placental parameters (body weight, stature, head circumference, chest circumference,

931 placental weight) were analyzed using Spearman's correlation test.

932




Figure 2






Figure 3

[Click here to access/download;Figure;Figure_3_revise2.pptx](#)

A



B



C






Figure 4

[Click here to access/download;Figure;Figure_4_revise2.pptx](#)

A



B

